BridgeBio Pharma, Inc. 8-K

What Happened
BridgeBio Pharma, Inc. (BBIO) announced on March 30, 2026, that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BBP-418, its investigational treatment for individuals living with limb-girdle muscular dystrophy type 2I / R9 (LGMD2I/R9). The company reported the event in a Current Report on Form 8-K (filed 2026-03-30, Accession No. 0001140361-26-011991) and attached a press release titled “BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9” as Exhibit 99.1.

Key Details

• Filing date: March 30, 2026 (Form 8-K, Item 8.01 Other Events).
• Event: NDA submitted to the FDA for BBP-418 targeting LGMD2I/R9.
• Press release: Attached as Exhibit 99.1 to the Form 8-K.
• The filing does not disclose a PDUFA date, approval timeline, or new financial guidance.

Why It Matters
An NDA submission is a major regulatory milestone that starts the FDA review process. For investors, this advances BBP-418 from development toward potential approval and commercialization, which could materially affect future revenue prospects if the drug is approved. Monitor BridgeBio updates and FDA communications (e.g., acceptance of the NDA, a PDUFA date, or requests for additional data) for news that could impact the company’s outlook.